Takeda shuttering manufacturing and R&D operations at Austrian AAV gene therapy plant, 190 layoffs expected

Takeda is winding down production and R&D operations at its adeno-associated virus (AAV) gene therapy plant in Orth, Austria, according to multiple news outlets. The decision will result in 190 employees losing their jobs.

The development comes almost a year after Takeda announced plans to divest the site in the following its decision to end discovery and preclinical activities on AAV gene therapy—the Orth site’s “core R&D competence.”